Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

Firas El Chaer, James McCloskey, Lindsay A.M. Rein, Randy A. Brown, Steven D. Green, Jeffrey J. Pu, Shuichi Shirane, Kazuya Shimoda, Michiko Ichii, Junichiro Yuda, Joseph Scandura, Sujan Kabir, Jason M Foulks, Jian Mei, Huyuan Yang, Mark Wade, Carl Stapinski, Claudia Lebedinsky, Raajit K Rampal

Blood (2022) 140 (Supplement 1): 594–595.

https://doi.org/10.1182/blood-2022-159086

Published: 2022

Journal Articles

Diet Quality of Long-Term Allogeneic and Autologous Stem Cell Transplant (HCT) Survivors

Nosha Farhadfar, MD, Debra Lynch Kelly, PhD, Lacey E. Mead, BS, Shalini Nair, Randy A. Brown, MD, John W. Hiemenz, MD, Jack W. Hsu, MD, Hemant S. Murthy, MD, W. Stratford May, MD PhD, John R. Wingard, MD, Wendy J Dahl, PhD

Blood (2019) 134 (Supplement_1): 4565.

https://doi.org/10.1182/blood-2019-127648

Published: 2019

Journal Articles

Digital Drug Screening and Computational Modeling Identifies Treatment Opportunities Despite Lack of Directly Actionable Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Blood (2017) 130 (Supplement 1): 3910.

https://doi.org/10.1182/blood.V130.Suppl_1.3910.3910

Published: 2017

Journal Articles

Poor Graft Function Following Autologous Stem Cell Transplant (ASCT): A Retrospective Analysis over Two Decades at a Transplant Center

Forat Lutfi, MD, William Paul Skelton, IV, MD, Emma Rosenau, Nosha Farhadfar, MD, Hemant S. Murthy, MD, W. Stratford May, MD PhD, John W. Hiemenz, MD, Christopher R. Cogle, MD, Randy A. Brown, MD, Sarah Wheeler, RPH, John R. Wingard, MD, Maxim Norkin, MD

Blood (2017) 130 (Supplement 1): 4529.

https://doi.org/10.1182/blood.V130.Suppl_1.4529.4529

Published: 2017

Journal Articles

Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Blood (2017) 130 (Supplement 1): 4277.

https://doi.org/10.1182/blood.V130.Suppl_1.4277.4277

Published: 2017

Journal Articles

A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Ddrug Sensitivity Testing

Blood (2017) 130 (Supplement 1): 2707.

https://doi.org/10.1182/blood.V130.Suppl_1.2707.2707

Published: 2017

Journal Articles

Impact of Novel Agents on Frequency of Second Salvage Autologous Transplantation in Patients with Multiple Myeloma

Prajwol Pathak, MD, Athira Unnikrishnan, MD, Fei Zou, PhD, Helen Leather, BPharm, Christopher R. Cogle, MD, Jack W Hsu, MD, Randy A. Brown, MD, John R. Wingard, MD, Maxim Norkin, MD PhD

Blood (2016) 128 (22): 5832.

https://doi.org/10.1182/blood.V128.22.5832.5832

Published: 2016

Journal Articles

Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with AML and MDS

Leylah Drusbosky, PhD, Elizabeth Wise, BS, Shireen Vali, PhD, Taher Abbasi, Ansu Kumar, Neeraj Kumar Singh, Kabya Basu, Chandan Kumar, Amjad Husain, Fei Zou, PhD, Caitlin Tucker, BS, Randy A Brown, MD, Maxim Norkin, MD PhD, John Hiemenz, MD, John R. Wingard, MD, Jack W Hsu, MD, Christopher R. Cogle, MD

Blood (2016) 128 (22): 594.

https://doi.org/10.1182/blood.V128.22.594.594

Published: 2016

Journal Articles

Effect of Melphalan 140 Mg/m 2 Versus 200 Mg/m 2 on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation

Lakshmikanth Katragadda, MD, Lindsay McCullough, MD, Yunfeng Dai, PhD, Jack W Hsu, MD, John W Hiemenz, MD, W. Stratford May, MD PhD, Christopher R. Cogle, MD, Maxim Norkin, MD PhD, Randy A Brown, MD, John R. Wingard, MD, Myron Chang, PhD, Jan S Moreb, MD

Blood (2015) 126 (23): 1988.

https://doi.org/10.1182/blood.V126.23.1988.1988

Published: 2015

Journal Articles

A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) Biopsy

Maxim Norkin, MD PhD, Myron Chang, PhD, An Qi, PhD, Helen Leather, BPharm, Lakshmikanth Katragadda, MD, Ying Li, MD PhD, Jan S Moreb, MD, W. Stratford May, MD PhD, Randy A. Brown, MD, Jack W. Hsu, MD, John W Hiemenz, MD, John R Wingard, MD, Christopher R. Cogle, MD

Blood (2015) 126 (23): 3852.

https://doi.org/10.1182/blood.V126.23.3852.3852

Published: 2015

Journal Articles

Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes

Lakshmikanth Katragadda, MD, Maxim Norkin, MD PhD, Myron Chang, PhD, Yunfeng Dai, PhD, Jan S Moreb, MD, W. Stratford May, MD PhD, Christopher R. Cogle, MD, Helen Leather, BPharm, Ying Li, MD PhD, Lamis K Eldjerou, MD, John W Hiemenz, MD, Randy A. Brown, MD, John R. Wingard, MD

Blood (2015) 126 (23): 3221.

https://doi.org/10.1182/blood.V126.23.3221.3221

Published: 2015

Journal Articles

Clinical and Laboratory Factors Influencing The Probability Of Complete Remission In AML Patients With Positive Day 14 Bone Marrows

Maxim Norkin, MD, PhD, Jan Moreb, MD, Helen Leather, BPharm, Randy A. Brown, MD, Jack W. Hsu, MD, John W Hiemenz, MD, W. Stratford May, MD, PhD, Myron N Chang, PhD, Qi An, Ying Li, MD, PhD, Christopher R Cogle, MD, John R Wingard, MD

Blood (2013) 122 (21): 1412.

https://doi.org/10.1182/blood.V122.21.1412.1412

Published: 2013

Journal Articles

Effect Of Cumulative Adverse Clinical Risk Factors On Patients With Multiple Myeloma Undergoing First GCSF Apheresis

Ilicia L. Shugarman, MD, Randy A Brown, MD, Christopher R Cogle, MD, John W Hiemenz, MD, W. Stratford May, MD, PhD, Maxim Norkin, MD, PhD, Helen Leather, BPharm, Xiaomin Lu, Michele W. Sugrue, John R. Wingard, MD, PhD, Jan Moreb, MD, Jack W Hsu

Blood (2013) 122 (21): 4520.

https://doi.org/10.1182/blood.V122.21.4520.4520

Published: 2013

Journal Articles

A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Daniel Turner, BS, Andres Gonzalez, BS, Leslie Pettiford, RN, Amy Meacham, MS, Elizabeth Wise, BS, Raphael C Bosse, BS, Dai Chaplin, PhD, Jack W. Hsu, MD, Randy A Brown, MD, John W Hiemenz, MD, Maxim Norkin, MD, PhD, John R Wingard, MD, Christopher R Cogle, MD

Blood (2013) 122 (21): 1463.

https://doi.org/10.1182/blood.V122.21.1463.1463

Published: 2013

Journal Articles

Peripheral Blood CD34 + Specific Donor Chimerism Analysis As an Early Indicator of Disease Relapse After Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes and Acute Myelogenous Leukemia.

Maxim Norkin, MD, PhD, Amy Meacham, MS, Mai H Ta, MT, Neil Benson, MS, Steven Goldstein, MD, Emma Rosenau, MPH, Jack W. Hsu, MD, Christopher R. Cogle, MD, John W Hiemenz, MD, Randy A. Brown, MD, John R. Wingard, MD

Blood (2012) 120 (21): 3074.

https://doi.org/10.1182/blood.V120.21.3074.3074

Published: 2012

Journal Articles

A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Christopher R Cogle, MD, Andres Gonzalez, BS, Leslie Pettiford, RN, Amy Meacham, MS, Elizabeth Wise, BS, Maxim Norkin, MD, PhD, David Chaplin, PhD, Jai Balkissoon, MD, Jack W Hsu, MD, Randy A Brown, MD, John W Hiemenz, MD, John R Wingard, MD

Blood (2012) 120 (21): 4335.

https://doi.org/10.1182/blood.V120.21.4335.4335

Published: 2012

Journal Articles

Negative Correlation Between the Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) and Total Hospital Stay in Patients Who Underwent Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT)

Napoleon Santos, DO, Randy A. Brown, MD, Myron N Chang, PhD, Christopher R Cogle, M.D., John W. Hiemenz, MD, W. Stratford May, Jan S Moreb, MD, Maxim Norkin, MD, PhD, John R. Wingard, MD, Baldeep Wirk, MD, Jack W Hsu, MD

Blood (2011) 118 (21): 4462.

https://doi.org/10.1182/blood.V118.21.4462.4462

Published: 2011

Journal Articles

CECA Results in Improved Response Rates and Ability to Proceed to Stem Cell Transplantation in Adult Refractory or Relapsed Acute Myeloid Leukemia

Sukanthini Subbiah, MD, Randy A. Brown, MD, Myron N Chang, PhD, Christopher R Cogle, M.D., John W. Hiemenz, MD, W. Stratford May, MD, PhD, Jan Moreb, MD, Maxim Norkin, MD, PhD, John R. Wingard, MD, Baldeep Wirk, MD, Jack W Hsu, MD

Blood (2011) 118 (21): 4299.

https://doi.org/10.1182/blood.V118.21.4299.4299

Published: 2011

Journal Articles

Reinduction Chemotherapy for AML: Comparison Between CECA, High Dose Cytarabine and CLAG-M

Christina Escobar, B.S., Sukanthini Subbiah, MD, Maxim Norkin, MD, PhD, Helen Leather, BPharm, Ashley Richards, Pharm.D., Randy A. Brown, MD, W. Stratford May, John R. Wingard, MD, Jack W Hsu, MD, Christopher R Cogle, M.D.

Blood (2011) 118 (21): 4301.

https://doi.org/10.1182/blood.V118.21.4301.4301

Published: 2011

Journal Articles

Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Scores Correlates with Increased Readmissions and Days In Hospital In Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplant

Szwed A. Ellen, DO, Jack W. Hsu, MD, Wei Hou, PhD, Randy A. Brown, MD, Christopher R. Cogle, MD, John W. Hiemenz, MD, W. Stratford May JR, MD, PhD, Jan S. Moreb, MD, Baldeep Wirk, MD, John R. Wingard, MD

Blood (2010) 116 (21): 4748.

https://doi.org/10.1182/blood.V116.21.4748.4748

Published: 2010

NARROW

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

Diet Quality of Long-Term Allogeneic and Autologous Stem Cell Transplant (HCT) Survivors

Digital Drug Screening and Computational Modeling Identifies Treatment Opportunities Despite Lack of Directly Actionable Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Poor Graft Function Following Autologous Stem Cell Transplant (ASCT): A Retrospective Analysis over Two Decades at a Transplant Center

Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Ddrug Sensitivity Testing

Impact of Novel Agents on Frequency of Second Salvage Autologous Transplantation in Patients with Multiple Myeloma

Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with AML and MDS

Effect of Melphalan 140 Mg/m 2 Versus 200 Mg/m 2 on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation

A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) Biopsy

Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes

Clinical and Laboratory Factors Influencing The Probability Of Complete Remission In AML Patients With Positive Day 14 Bone Marrows

Effect Of Cumulative Adverse Clinical Risk Factors On Patients With Multiple Myeloma Undergoing First GCSF Apheresis

A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Peripheral Blood CD34 + Specific Donor Chimerism Analysis As an Early Indicator of Disease Relapse After Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes and Acute Myelogenous Leukemia.

A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Negative Correlation Between the Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) and Total Hospital Stay in Patients Who Underwent Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT)

CECA Results in Improved Response Rates and Ability to Proceed to Stem Cell Transplantation in Adult Refractory or Relapsed Acute Myeloid Leukemia

Reinduction Chemotherapy for AML: Comparison Between CECA, High Dose Cytarabine and CLAG-M

Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Scores Correlates with Increased Readmissions and Days In Hospital In Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only